journal of hematology oncology pharmacy - december 2011, vol 1, no 4

Download Journal of Hematology Oncology Pharmacy - December 2011, VOL 1, NO 4

Post on 30-Mar-2016

214 views

Category:

Documents

0 download

Embed Size (px)

DESCRIPTION

The Peer-Reviewed Forum for Oncology Pharmacy Practice

TRANSCRIPT

  • HEMATOLOGYONCOLOGYPHARMACY

    JOURNAL OFVOL 1 I NO 4

    DECEMBER 2011

    THE PEER-REVIEWED FORUM FOR ONCOLOGY PHARMACY PRACTICETM

    2011 Green Hill Healthcare Communications, LLCwww.JHOPonline.com

    CLINICAL CONTROVERSIESBevacizumab in Metastatic Breast Cancer: Ready for Prime Time? CON: Katherine Mandock, PharmD, BCPS;

    Scott A. Soefje, PharmD, BCOPPRO: Val R. Adams, PharmD, BCOP, FCCP

    REVIEW ARTICLESCurrent Practice in the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in AdultsLisa K. Lohr, PharmD, BCOP, BCPS

    The Evolution of Tyrosine Kinase Inhibitor Therapy: Improving Outcomes in Patients with Newly Diagnosed Chronic Myelogenous LeukemiaNatalie J. Greisl, PharmD; Christopher A. Fausel, PharmD, BCPS, BCOP

    From the LiteratureConcise Reviews of Studies Relevant to Hematology Oncology Pharmacy Robert J. Ignoffo, PharmD, FASHP, FCSHP

    1-Cover_Layout 1 12/19/11 1:12 PM Page 1

  • Find out whats new

    www.XGEVA.com

    2011 Amgen Inc. All rights reserved. 61187-R1-V1

    Visit XGEVA.com

    1-Cover_Layout 1 12/19/11 11:12 AM Page 2

  • 3www.JHOPonline.com l Journal of Hematology Oncology Pharmacy Vol 1, No 4 l December 2011

    EDITORIAL BOARD

    CLINICAL CONTROVERSIESChristopher Fausel, PharmD, BCPS, BCOP Clinical DirectorOncology Pharmacy ServicesIndiana University Simon Cancer CenterIndianapolis, IN

    PRACTICAL ISSUES IN PHARMACY MANAGEMENT Timothy G. Tyler, PharmD, FCSHP Director of PharmacyComprehensive Cancer CenterDesert Regional Medical CenterPalm Springs, CA

    ORIGINAL RESEARCH R. Donald Harvey, PharmD, FCCP, BCPS, BCOPAssistant Professor, Hematology/Medical Oncology Department of Hematology/Medical OncologyDirector, Phase 1 UnitWinship Cancer InstituteEmory University, Atlanta, GA

    REVIEW ARTICLESScott Soefje, PharmD, BCOPAssociate Director, Oncology PharmacySmilow Cancer Hospital at Yale New HavenYale New Haven HospitalNew Haven, CT

    FROM THE LITERATURERobert J. Ignoffo, PharmD, FASHP, FCSHPProfessor of Pharmacy, College of PharmacyTouro UniversityCalifornia Mare Island Vallejo, CA

    Patrick J. Medina, PharmD, BCOPAssociate ProfessorDepartment of PharmacyUniversity of Oklahoma College of PharmacyOklahoma City, OK

    Val R. Adams, PharmD, BCOP, FCCPAssociate Professor, Pharmacy Program Director, PGY2 Specialty ResidencyHematology/OncologyUniversity of Kentucky College of PharmacyLexington, KY

    SECTION EDITORS

    CO-EDITORS-IN-CHIEF

    Joseph Bubalo, PharmD, BCPS, BCOPAssistant Professor of MedicineOncology Clinical Specialist and Oncology LeadOHSU Hospital and ClinicsPortland, OR

    Sandra Cueller, PharmD, BCOPDirectorOncology Specialty ResidencyUniversity of Illinois at Chicago Medical CenterChicago, IL

    Sachin Shah, PharmD, BCOPAssociate ProfessorTexas Tech University Health Sciences CenterDallas, TX

    Steve Stricker, PharmD, MS, BCOP Assistant Professor of Pharmacy PracticeSamford University McWhorter School of PharmacyBirmingham, AL

    John M. Valgus, PharmD, BCOPHematology/Oncology Senior Clinical PharmacySpecialistUniversity of North Carolina Hospitals and ClinicsChapel Hill, NC

    Daisy Yang, PharmD, BCOP Clinical Pharmacy SpecialistUniversity of Texas M. D. Anderson Cancer CenterHouston, TX

    EDITORS-AT-LARGE

    2-EditBoard_Cover 12/19/11 11:18 AM Page 3

  • 4 l Journal of Hematology Oncology Pharmacy l www.JHOPonline.com December 2011 l Vol 1, No 4

    Senior Vice President, Sales & Marketing

    Philip Pawelkophil@greenhillhc.com

    PublisherJohn W. Hennessy

    john@greenhillhc.com732.992.1886

    Editorial DirectorDalia Buffery

    dalia@greenhillhc.com732.992.1889

    Associate EditorsBrett KaplanLara J. Lorton

    Editorial AssistantJennifer Brandt732.992.1536

    Directors, Client ServicesJoe Chanley

    joe@greenhillhc.com732.992.1524

    Jack Iannacconejack@greenhillhc.com

    732.992.1537

    Production ManagerStephanie Laudien

    Quality Control DirectorBarbara Marino

    Business ManagerBlanche Marchitto

    blanche@greenhillhc.com

    Editorial Contact:Telephone: 732.992.1536

    Fax: 732.656.7938E-mail: JHOP@greenhillhc.com

    TABLE OF CONTENTS

    DECEMBER 2011 VOLUME 1, NUMBER 4

    Journal of Hematology Oncology Pharmacy, ISSN applied for (print); ISSN applied for (online), is published 4 times a year by Green Hill Healthcare Communications, LLC, 241 Forsgate Drive,Suite 205C, Monroe Twp, NJ 08831. Telephone: 732.656.7935. Fax: 732.656.7938. Copyright 2011 by Green Hill Healthcare Communications LLC. All rights reserved. Journal ofHematology Oncology Pharmacy logo is a trademark of Green Hill Healthcare Com munications, LLC. No part of this publication may be reproduced or transmitted in any form or by anymeans now or hereafter known, electronic or mechanical, including photocopy, recording, or any informational storage and retrieval system, without written permission from the Publisher.Printed in the United States of America.

    EDITORIAL CORRESPONDENCE should be addressed to EDITORIAL DIRECTOR, Journal of Hematology Oncology Pharmacy, 241 Forsgate Drive, Suite 205C, Monroe Twp, NJ08831. E-mail: JHOP@greenhillhc.com. YEARLY SUBSCRIPTION RATES: United States and possessions: individuals, $105.00; institutions, $135.00; single issues, $17.00. Orders will bebilled at individual rate until proof of status is confirmed. Prices are subject to change without notice. Correspondence regarding permission to reprint all or part of any article published inthis journal should be addressed to REPRINT PERMISSIONS DEPARTMENT, Green Hill Healthcare Commun i cations, LLC, 241 Forsgate Drive, Suite 205C, Monroe Twp, NJ 08831.The ideas and opinions expressed in Journal of Hematology Oncology Pharmacy do not necessarily reflect those of the Editorial Board, the Editorial Director, or the Publisher. Publication ofan advertisement or other product mention in Journal of Hematology Oncology Pharmacy should not be construed as an endorsement of the product or the manufacturers claims. Readers areencouraged to contact the manufacturer with questions about the features or limitations of the products mentioned. Neither the Editorial Board nor the Publisher assumes any responsibilityfor any injury and/or damage to persons or property arising out of or related to any use of the material contained in this periodical. The reader is advised to check the appropriate medical lit-erature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindi-cations. It is the responsibility of the treating physician or other healthcare professional, relying on independent experience and knowledge of the patient, to determine drug dosages and thebest treatment for the patient. Every effort has been made to check generic and trade names, and to verify dosages. The ultimate responsibility, however, lies with the prescribing physician.Please convey any errors to the Editorial Director.

    CLINICAL CONTROVERSIES 6 Bevacizumab in Metastatic Breast Cancer: Ready for Prime Time?

    CON: Katherine Mandock, PharmD, BCPS; Scott A. Soefje, PharmD, BCOPPRO: Val R. Adams, PharmD, BCOP, FCCP

    REVIEW ARTICLES13 Current Practice in the Prevention and Treatment of Chemotherapy-Induced

    Nausea and Vomiting in AdultsLisa K. Lohr, PharmD, BCOP, BCPS

    25 The Evolution of Tyrosine Kinase Inhibitor Therapy: Improving Outcomes in Patients with Newly Diagnosed Chronic Myelogenous LeukemiaNatalie J. Greisl, PharmD; Christopher A. Fausel, PharmD, BCPS, BCOP

    FROM THE LITERATURE36 Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy

    Robert J. Ignoffo, PharmD, FASHP, FCSHP

    PUBLISHING STAFF

    MISSION STATEMENTThe Journal of Hematology Oncology Pharm -acy is an independent, peer-reviewed jour-nal founded in 2011 to provide hematologyand oncology pharmacy practitioners andother healthcare professionals with high-quality peer-reviewed information rele-vant to hematologic and oncologic condi-tions to help them optimize drug therapyfor patients.

    THE PEER-REVIEWED FORUM FOR ONCOLOGY PHARMACY PRACTICETM

    3-TOC_Cover 12/21/11 2:15 PM Page 4

  • 3-TOC_Cover 12/19/11 11:17 AM Page 5

  • CLINICAL CONTROVERSIES

    6 l Journal of Hematology Oncology Pharmacy l www.JHOPonline.com December 2011 l Vol 1, No 4

    Controversy has developed over the label indica-tions for bevacizumab in metastatic breast cancer(MBC). The US Food and Drug Administration(FDA) had granted accelerated approval for bevacizumabfor the treatment of MBC based on clinical trials thatdemonstrated a progression-free survival (PFS) advantage.This controversy begins when the postapproval trialsrequired with the FDA approval failed to demonstrate anoverall survival (OS) advantage in addition to the PFSadvantage. Subsequently, the Oncology Drug AdvisoryCommittee (ODAC) recommended, and ultimately theFDA issued its decision, to remove bevacizumabs currentlabeled indication for MBC.1

    In this debate we take the side that supports theFDAs final decision to remove that indication. Our posi-tion is based on the arguments that reflect the regulato-ry, efficacy, safety, and economic perspectives. We willdemonstrate that this indication does not meet the stan-dard required for labeled indications, that the efficacy forthe indication does not show a clinical benefit, thatthere are serious safety concerns, and that the economicimpact is too great to justify the drugs approval.

    The FDA Modernization Act of 1997 permitted theFDA to approve the marketing of drugs upon a deter-mination that the product has an effect on a clinicalendpoint or on a surrogate endpoint that is reasonablylikely to predict clinical benefit.2 This is ex

Recommended

View more >